Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes

Journal of Surgical Oncology

Volumn 105, Issue 6, 2012, Pages 595-600

  Roland, Christina L ^a   Bian, Aihua ^b   Mansour, John C ^a   Yopp, Adam C ^a   Balch, Glen C ^a   Sharma, Rohit ^a   Xie, Xian Jin ^b   Schwarz, Roderich E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

pancreatic neuroendocrine tumor; SEER population data; survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CARCINOMA; FEMALE; GASTRINOMA; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; INSULINOMA; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NEUROENDOCRINE DISEASE; NEUROENDOCRINE ISLET CELL TUMOR; OVERALL SURVIVAL; PANCREAS ISLET CELL CARCINOMA; PANCREAS ISLET CELL TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; VIPOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, ISLET CELL; FEMALE; HUMANS; INSULINOMA; LYMPH NODES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 84859723882     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22118     Document Type: Article

References (34)

1. Mansour JC, Chen H,: Pancreatic endocrine tumors. J Surg Res 2004; 120: 139-161.
2. Bilimoria KY, Talamonti MS, Tomlinson JS, et al.: Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg 2008; 247: 490-500.
3. Fesinmeyer MD, Austin MA, Li CI, et al.: Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1766-1773.
4. Hill JS, McPhee JT, McDade TP, et al.: Pancreatic neuroendocrine tumors: The impact of surgical resection on survival. Cancer 2009; 115: 741-751.
5. Solorzano CC, Lee JE, Pisters PW, et al.: Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. Surgery 2001; 130: 1078-1085.
6. Yao JC, Eisner MP, Leary C, et al.: Population-based study of islet cell carcinoma. Ann Surg Oncol 2007; 14: 3492-3500.
7. Fendrich V, Waldmann J, Bartsch DK, et al.: Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 2009; 6: 419-428.
8. Franko J, Feng W, Yip L, et al.: Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg 2010; 14: 541-548.
9. Martin RC, Kooby DA, Weber SM, et al.: Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg 2011; 15: 175-183.
10. Sarmiento JM, Heywood G, Rubin J, et al.: Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37.
11. Sarmiento JM, Que FG,: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003; 12: 231-242.
12. Chen H, Hardacre JM, Uzar A, et al.: Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg 1998; 187: 88-92; discussion 92-93.
13. Chamberlain RS, Canes D, Brown KT, et al.: Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445.
14. House MG, Cameron JL, Lillemoe KD, et al.: Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 2006; 10: 138-145.
15. Capurso G, Bettini R, Rinzivillo M, et al.: Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: A systematic review. Neuroendocrinology 2011.
16. Modlin IM, Gustafsson BI, Pavel M, et al.: A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology 2010; 92: 143-157.
17. Bergestuen DS, Aabakken L, Holm K, et al.: Small intestinal neuroendocrine tumors: Prognostic factors and survival. Scand J Gastroenterol 2009; 44: 1084-1091.
18. Bilimoria KY, Bentrem DJ, Merkow RP, et al.: Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205: 558-563.
19. Edge SB, Byrd DR, Compton CC, et al.: AJCC cancer staging manual. New York: Springer; 2009.
20. Bilimoria KY, Tomlinson JS, Merkow RP, et al.: Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: Analysis of 9,821 patients. J Gastrointest Surg 2007; 11: 1460-1467; discussion 1467-1469.
21. Jann H, Roll S, Couvelard A, et al.: Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer 2011.
22. Scarpa A, Mantovani W, Capelli P, et al.: Pancreatic endocrine tumors: Improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833.
23. Surveillance Epidemiology and End Results (SEER) Program: public use data (1973-2004). In 2007.
24. Percy A, Shanmugaratnam K, Whelan S, et al.: International Classification of Diseases for Oncology (ICD-O), third edition. Geneva: World Health Organization; 2005.
25. Kaplan EL, Meier P,: Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457-481.
26. 2/E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584.
27. Cox DR,: Regression models and life tables. J R Stat Soc Series B 1972; 29: 187-220.
28. Pelosi G, Bresaola E, Bogina G, et al.: Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27: 1124-1134.
29. Yao JC, Hassan M, Phan A, et al.: One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
30. Fossa SD, Cvancarova M, Chen L, et al.: Adverse prognostic factors for testicular cancer-specific survival: A population-based study of 27,948 patients. J Clin Oncol 2011.
31. Patel MK, Patel DA, Lu M, et al.: Impact of marital status on survival among women with invasive cervical cancer: Analysis of population-based surveillance, epidemiology, and end results data. J Low Genit Tract Dis 2010; 14: 329-338.
32. Sprehn GC, Chambers JE, Saykin AJ, et al.: Decreased cancer survival in individuals separated at time of diagnosis: Critical period for cancer pathophysiology? Cancer 2009; 115: 5108-5116.
33. Goodwin JS, Hunt WC, Key CR, Samet JM,: The effect of marital status on stage, treatment, and survival of cancer patients. JAMA 1987; 258: 3125-3130.
34. Bilimoria KY, Bentrem DJ, Ko CY, et al.: Validation of the 6th edition AJCC Pancreatic Cancer Staging System: Report from the National Cancer Database. Cancer 2007; 110: 738-744.